Services > Assay Development

Assay Development: Your IVD experts from concept to high volume manufacture.

We can work with you to translate your existing assay into a quantitative electrochemical assay.

Talk to us today

• Gii-based surface molecule modification & immobilisation

• Customised non-specific adsorption strategies

• Scale up

• Preconcentration and required purification steps

• Incubation times and temperatures

• Reagent formulation

• Automation and microfluidics

• Determination of sensitivity, selectivity and limit of detection

• Instrumentation

Our Capabilities

Custom Electrodes

Customisable electrodes for customer needs.

Photograph of someone looking at graphs on a laptop

Reproducibility and Precision

Explore analytical performance (dynamic range).

Gii-Sens in an adaptor with a pipette dropping a sample onto the electrode

Surface Chemistry Development

Develop surface chemistries to target specific biological material (Protein, DNA, Aptamer, Antibody).

New Assay Formats

Explore different assay formats (sandwich, direct) to improve signal sensitivity.

Quantify Assays

Develop existing assay chemistry into quantitative electrochemical assay.

Target Analyte Sensing

Establish the electrochemical immunoassay procedure and parameters yielding the most sensitive analytical assay.

Multidisciplinary Approach

Integration of dispensing techniques & microfluidics.

Close up of dropper and drop on Gii-Sens with Adapter

The limited Point-of-Care market share is due to a limited menu of expensive tests. Gii-Sens and our assay development services open a significant opportunity to expand POC solutions due to the performance improvements realised at a scalable cost.

Case Study:

SARS-CoV-2 / COVID Amplification-Free RNA Detection.

Integrated Graphene’s revolutionary pure 3D Graphene Foam sensing electrode, Gii-Sens, has the properties to enable the development of the world's most sensitive biosensor.

Gii-Sens enables amplification-free, label-free and enzyme-free detection.

This project will convert an RT-PCR laboratory test for SARS-CoV-2 to a rapid test for the point of need. Such an advancement will be a real game-changer for the medical diagnostic industry and will vastly reduce patient time to results. 

By showcasing the benefits of Gii-Sens within this viral RNA model, it raises the question: what other targets of interest could be translated to the point of need?